GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Deferoxamine - DESFERAL injection

Local official-label summaryBase record retrieved 2026-09-10See the evidence for this drug2 sources available - open source summaries, references and comparisons

DESFERAL / deferoxamine mesylate

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Qualitative low-end dosing does not override severe-renal contraindication

The selected sources contraindicate severe renal disease/anuria but also advise low-end dosing in renal impairment. Dialyzability is described in overdose management.

Before applying: Do not invent a numerical severity boundary or a dialysis supplement. Specialist off-label aluminum regimens are not adjudicated here.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Deferoxamine - DESFERAL injection

Product / population
DESFERAL injection in its labeled iron-intoxication/iron-overload context; not a newly constructed aluminum-overload dialysis regimen.
Renal measure
Qualitative renal impairment; severe renal disease/anuria
Before using this finding

Do not invent a numerical renal threshold or dialysis supplement from qualitative restriction and removal information.

Selected named sections only; not a complete monograph or independent clinical approval.

Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.

Renal dosing, restrictions and evidence limits

The manufacturer label contraindicates severe renal disease or anuria and advises low-end dose selection in renal impairment without providing a clearance ladder. Monitor renal function for creatinine elevation, acute renal failure and tubular disorders. Its overdose section describes ready dialyzability; that observation is not a labeled routine dialysis replacement regimen. The retrieved document prints a September 2022 revision. These selected restrictions do not establish present product availability or adjudicate specialist off-label aluminum treatment.

Source revision: 9/2022 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://www.novartis.com/us-en/sites/novartis_us/files/desferal.pdf

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Deferoxamine - DESFERAL injection

Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

Removal information only - not a dialysis regimen

Read the source and its limits

GlobalRPh RX List - DESFERAL

Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

Removal information only - not a dialysis regimen

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Deferoxamine - DESFERAL injection

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Do not invent a numerical renal threshold or dialysis supplement from qualitative restriction and removal information.

Dialysis evidence: Removal information only - not a dialysis regimen

DESFERAL injection in its labeled iron-intoxication/iron-overload context; not a newly constructed aluminum-overload dialysis regimen.

Renal method: Qualitative renal impairment; severe renal disease/anuria
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - DESFERAL

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Keep severe renal disease/anuria separate from the lesser-impairment low-end-dose instruction.

Dialysis evidence: Removal information only - not a dialysis regimen

DESFERAL injection in its labeled iron-intoxication/iron-overload context; not a newly constructed aluminum-overload dialysis regimen.

Renal method: Qualitative renal impairment and severe renal disease/anuria; no numeric threshold supplied
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Qualitative low-end dosing does not override severe-renal contraindication

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

qualitative restriction and removal only

Qualitative low-end dosing does not override severe-renal contraindication

The selected sources contraindicate severe renal disease/anuria but also advise low-end dosing in renal impairment. Dialyzability is described in overdose management.

How to use this: Do not invent a numerical severity boundary or a dialysis supplement. Specialist off-label aluminum regimens are not adjudicated here.

GlobalRPh RX List - DESFERALDeferoxamine - DESFERAL injection

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeDeferoxamine - DESFERAL injectionGlobalRPh RX List - DESFERAL
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/desferal-drug/

Exact product and population

DESFERAL injection in its labeled iron-intoxication/iron-overload context; not a newly constructed aluminum-overload dialysis regimen.

RDM60-SCOPE-deferoxamine-desferal · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Deferoxamine - DESFERAL injection

Open original reference

Open / share this exact local source

Novartis Pharmaceuticals Corporation / manufacturer prescribing information · DESFERAL injection in its labeled iron-intoxication/iron-overload context; not a newly constructed aluminum-overload dialysis regimen.

Renal method: Qualitative renal impairment; severe renal disease/anuria
Source date: 9/2022
Retrieved: 2026-09-10

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Do not invent a numerical renal threshold or dialysis supplement from qualitative restriction and removal information.

Dialysis evidence: Removal information only - not a dialysis regimen

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The manufacturer label contraindicates severe renal disease or anuria and advises low-end dose selection in renal impairment without providing a clearance ladder. Monitor renal function for creatinine elevation, acute renal failure and tubular disorders. Its overdose section describes ready dialyzability; that observation is not a labeled routine dialysis replacement regimen. The retrieved document prints a September 2022 revision. These selected restrictions do not establish present product availability or adjudicate specialist off-label aluminum treatment.

RDM60-official-deferoxamine-desferal-24e19913cf-C1 · Source locator: 4; 5.3; 8.6; 10; PDF renal-toxicity page rendered

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.

Source identity and provenance
Source family
product_label
Source
https://www.novartis.com/us-en/sites/novartis_us/files/desferal.pdf
Retrieved
2026-09-10
Exact label title
Deferoxamine - DESFERAL injection
Labeler
Novartis Pharmaceuticals Corporation
Label revision
9/2022
Renal-function method
Qualitative renal impairment; severe renal disease/anuria
Source date/version
9/2022
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
053db19f2a15e5116685d6e732a49badd7012552a50ed1efbae73f32b9b1888b
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - DESFERAL

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · DESFERAL injection in its labeled iron-intoxication/iron-overload context; not a newly constructed aluminum-overload dialysis regimen.

Renal method: Qualitative renal impairment and severe renal disease/anuria; no numeric threshold supplied
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Keep severe renal disease/anuria separate from the lesser-impairment low-end-dose instruction.

Dialysis evidence: Removal information only - not a dialysis regimen

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The mirror contraindicates severe renal disease or anuria because drug and iron chelate are predominantly renally excreted. For renal impairment it advises selection at the low end of the dose range, without numerical CrCl bands. Increased creatinine, acute renal failure and tubular injury are reported; monitor renal function. Dialyzability appears in overdose management and does not provide a maintenance or post-dialysis replacement schedule. The qualitative low-dose instruction does not override the severe-disease contraindication.

RDM60-rxlist-deferoxamine-desferal-9a3f0b116d-C1 · Source locator: Renal impairment; contraindications; renal toxicity; overdose

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. See the separately attributed official source; concordance is limited to selected sections.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/desferal-drug/
Retrieved
2026-09-10
Renal-function method
Qualitative renal impairment and severe renal disease/anuria; no numeric threshold supplied
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
f2f3a91c6dbe87a4912ea8c0c8ccd6ef3b0c8163593ab653473cfad9e64efe8f

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/desferal-drug/
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
18c8df11eea79c2ff39a19c48e99c2640a4b69db06d0be241966a16510c622d1
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report